IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IRADIMED CORPORATION on January 18, 2023. The filing announces preliminary financial results for the fourth quarter ended December 31, 2022, and provides guidance for the full year 2023. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol IRMD.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body text. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial data and analysis of changes.
Guidance, Outlook, and Risks
Management has issued 2023 guidance as part of the press release referenced in this filing. The text explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated. No specific risks, contingencies, or unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 18, 2023) for specific Q4 2022 revenue and earnings figures.
- Verify the full-year 2023 revenue and earnings guidance provided in the press release.
- Confirm the company's liquidity position and debt levels as detailed in the referenced press release.
- Check for any forward-looking statements and associated risk factors in the press release.